• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Rheumatology

Show Search
Hide Search
  • About Us
    • Our History
    • Our Faculty
    • Rheumatology Fellowship
    • Administrative Core
    • Contact Us
    • eNews Signup
  • Make an Appointment
    • Clinic Information
    • Specialty Clinics
  • Our Research
    • Current Research Studies
    • Andrade Lab
    • Darrah Lab
    • Konig Lab
    • Rosen Casciola Lab
    • RDRCC
    • Bayview Immunomics Core (BIC)
  • Charitable Giving
    • Dr. John Welton Fellowship in Rheumatology
    • Dr. Ira T. Fine Discovery Fund
    • Dr. Nadia D. Morgan Memorial Fund
  • News
    • LEAP Magazine
  • Education
    • Advances in the Diagnosis and Treatment of the Rheumatic Diseases Course
    • RheumTV – Patient Education Video Library
Home / News / Enzyme-activating antibodies are linked to severe rheumatoid arthritis

Enzyme-activating antibodies are linked to severe rheumatoid arthritis

July 22, 2013 By Johns Hopkins Rheumatology

A new finding by the Johns Hopkins Division of Rheumatology provides insight into how the immune system may increase joint damage in rheumatoid arthritis (RA). By studying blood samples from patients with RA, Darrah et.al found a unique antibody that binds to an enzyme, called PAD4, known to be involved in the disease. This newly discovered antibody turns the enzyme on and is found in the blood of patients with the most severe form of RA, in which bone destruction is found.

PAD4 is an enzyme that normally modifies proteins in the body to change their function. For reasons that are still unclear, proteins modified by PAD4 and enzymes like it, become targets of the immune system  in RA. PAD4  can be thought of as a fuel pump, providing fuel for the fire that is the ongoing disease in RA. The more active the enzyme is, the more fuel (or modified protein) that is available to the immune system, and the fire becomes larger and hotter (i.e. worse disease). In contrast, if PAD4 enzymes are less active, there is less fuel present and the fire will be smaller.

In experiments looking at the ability of the enzyme to function, the group found that in the presence of the antibody, the PAD4 enzyme could function 500-times better under conditions normally found in the body. In other words, these antibodies turned on the fuel pump, increasing the amount of fuel available to activate the immune system and may explain why patients with this antibody have the worst disease. This newly discovered antibody may therefore identify patients who would benefit the most from being treated with aggressive therapy or from the addition of medications that inhibit PAD4 enzyme activity.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Filed Under: News, Research Tagged With: Featured 2

Johns Hopkins Rheumatology

The Division of Rheumatology is a thriving clinical and academic center, which concentrates clinically on providing the most outstanding care to patients affected by a variety of common and uncommon rheumatic disorders.

Use of this Site

All information contained within the Johns Hopkins Division of Rheumatology website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

  • Our History
  • Our Faculty
  • Postdoctoral Fellowships
  • Administrative Core
  • Contact Us
  • eNews Signup

Rheumatology News

RheumTV Logo

Rheum.TV is an educational platform created to help patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit RheumTV

Footer

Rheumatology Specialty Care Centers

  • Johns Hopkins Arthritis Center
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect with Us

  • Facebook
  • Twitter
  • YouTube
U.S. News and World Report Rankings Badge

Johns Hopkins Medicine

© 2023 Johns Hopkins Rheumatology - Patient Privacy